The 26 references in paper G. Gorodetskaya I., V. Kukes G., S. Belkov A., R. Kazakov E., S. Serebrova Yu., O. Muslimova V., T. Rodina A., A. Aleksandrov A., Г. Городецкая И., В. Кукес Г., С. Белков А., Р. Казаков Е., С. Сереброва Ю., О. Муслимова В., Т. Родина А., А. Александров А. (2018) “Фармакогенетическое тестирование в оптимизации терапии сахарного диабета 2 типа препаратами сульфонилмочевины // Pharmacogenetic testing in the treatment of type 2 diabetes with sulfonylurea drugs” / spz:neicon:vedomostincesmp:y:2017:i:4:p:233-241

1
Dedov II, Shestakova MV, Mayorov AYu, Vikulova OK, Galstyan GR, Kuraeva TL, et al. Standards of specialized diabetes care. Diabetes mellitus 2017; 20(1S): 1–112 (in Russian).
(check this in PDF content)
2
Kukes VG, Sychev DA, Andreev DA, Arkhipov VV, Batischeva GA, Berdnikova NG, et al. Ñlinical pharmacology. 5th ed. Moscow: GEOTAR-Media; 2015 (in Russian).
(check this in PDF content)
3
Reaven GM. Role of insulin resistance in human disease: Banting lecture 1988. Diabetes 1988; 3737(12): 1595–607.
(check this in PDF content)
4
Matschinsky F, Liang Y, Kesavan P, Wang L, Froguel P, Velho G, et al. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest. 1993; 3792(5): 2092–8.
(check this in PDF content)
5
Florez JC. The genetics of type 2 diabetes: a realistic appraisal. J Clin Endocrinol Metab. 2008; 3793(12): 4633–42.
(check this in PDF content)
6
Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 3756(8): 2178–82.
(check this in PDF content)
7
Shvedova AM. Pharmacoepidemiological and pharmacoeconomic evaluation of oral hypoglycemic therapy of diabetes mellitus of the 2nd type in the ambulatory practice. International journal of endocrinology 2007; 4(10). Available from: http://www.mif-ua.com/archive/article/2875 (in Russian).
(check this in PDF content)
8
Shestakova MV. Actual clinical practice of treatment of diabetes type 2 in the Russian Federation according to the prospective open observational program «DIA-CONTROL». Diabetes mellitus 2011; (4): 75–80 (in Russian).
(check this in PDF content)
9
Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in helht and disease. Diabetologia 1999; 3742(8): 903–19.
(check this in PDF content)
10
Nedosugova LV, Balabolkin MI. Algorithm treatment diabetes type 2 diabetes. Moscow: MedExpertPress; 2008 (in Russian).
(check this in PDF content)
11
Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta–cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994; 371191(2): 267–77.
(check this in PDF content)
12
Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20(7): 1087–92.
(check this in PDF content)
13
Attorrese G, Massi-Benedetti M. Quality and behaviour generic versus amaryl under stress conditions. Diabetes Technology and Therapeutics 2007; 379(3): 287–96.
(check this in PDF content)
14
Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002; 3725(8): 1271–6.
(check this in PDF content)
15
Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC. Similar reduction of first- and second-phase â-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989; 3738(8): 767–72.
(check this in PDF content)
16
Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications 2004; 3718(6): 367–76.
(check this in PDF content)
17
Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001; 3717(6): 467–73.
(check this in PDF content)
18
Schernthaner G, Grimaldi A, Di-Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004; 3734(8): 535–42.
(check this in PDF content)
19
Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5’-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 3791(6): 2334–9.
(check this in PDF content)
20
Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009; 3741(5): 387–90.
(check this in PDF content)
21
Nikolac N, Simundic AM, Katalinic D, Topic E, Cipak A, Zjacic Rotkvic V. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res. 2009; 40(5): 387–92.
(check this in PDF content)
22
Balabolkin MI, Kreminskaya VM, Klebanova EM. Modern tactics of treatment of diabetes mellitus type 2. Consilium medicum 2001; 373(11): 535–40 (in Russian).
(check this in PDF content)
23
Fronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 1984; 377(1): 72–80.
(check this in PDF content)
24
Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischemic preconditioning. A double-blind, placebo-controlled evolution of glimepiride and glibenclamide. Eur Heart J. 1999; 20(6): 439–46.
(check this in PDF content)
25
Nagashima K, Takahashi A, Ikeda H, Hamasaki A, Kuwamura N, Yamada Y, et al. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmacological properties and tissue selectivity. Diabetes Res Clin Pract. 2004; 66 (Suppl. 1): S75–8.
(check this in PDF content)
26
Indiana University. Department of Medicine. P450 Drug Interaction
(check this in PDF content)